XKDCT 225
Alternative Names: Autologous targeted claudin18.2 chimeric antigen receptor T cell injection; XKDCT-225Latest Information Update: 04 Feb 2025
Price :
$50 *
At a glance
- Originator Shenzhen Celconta Life Science
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 14 Jan 2025 Phase-I clinical trials in Solid tumours (Late-stage disease) in China (Parenteral) (NCT06782425)